Clinical Trial Update: A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II trial of gene-modified WT1 TCR therapy in patients with myelodysplastic syndromes and acute myeloid leukaemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukaemia
• Myelodysplastic Syndromes

Drugs mentioned

• WT1 TCR therapy (gene-modified) (WT1-specific T-cell receptor therapy)

Snippet

Sponsor: Cell Medica Ltd | Conditions: Myelodysplastic Syndromes (MDS), Acute Myeloid Leukaemia (AML) | Phase 1, Phase 2 | Status: COMPLETED